Market Currents
Celgene (CELG +2.8%) gains on an upgrade to Buy on valuation at Argus, citing the company's...
-
Friday, June 29, 2012, 2:07 PM ETCelgene (CELG +2.8%) gains on an upgrade to Buy on valuation at Argus, citing the company's reiterated guidance following the Revlimid setback.
Other date
HEALTHCARE ETFs IN FOCUS
Latest Healthcare Articles
